

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dina Ben-Yehuda

Confirmation No.: 5095

Application No.: 10/559,639

Attorney Docket No: 7640-X05-046

Filed: Not Assigned

Group Art Unit: TBD

For: LIVIN-DERIVED PEPTIDES, COMPOSITIONS
AND USES THEREOF

Examiner: TBD

RESPONSE TO NOTIFICATION

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Dear Sir:

In response to the Notification mailed February 27, 2007, a copy of which is enclosed, please enter the following into the file of the above-entitled application. In accordance with USPTO practice, each section of this Response begins on a separate sheet. Applicants submit these amendments and remarks serve to clarify the present invention and are independent of patentability.

Amendment to the Specification

Please enter the enclosed substitute Sequence Listing into the specification. The Sequence Listing is being submitted in both computer readable form and paper copy. Furthermore, a separate Sequence Listing Submission Statement is also being submitted.

Lack of Compliance of Nucleotide Sequence Disclosure with 37 C.F.R. 1.821(e)

The sequence disclosure was deemed not to comply with 37 C.F.R. §1.821(e). The paper copy of the Sequence Listing was cited as not being the same as the computer readable form of the Sequence Listing. In accordance with 37 C.F.R. §1.825(a), Applicants submit herewith and requests entry of a substitute copy of the Sequence Listing. The Sequence Listing is being submitted in both computer readable form and paper copy. Furthermore, a separate Sequence Listing Submission Statement is also being submitted. Applicants submit that the content of the substitute copy of the Sequence Listing is the same as the computer readable copy originally filed. The substitute copy of the Sequence Listing includes no new matter.

Conclusion

In light of the foregoing remarks, this application is now in condition for an examination on the merits, and early action is respectfully requested. If any questions remain regarding this response or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

No fee is believed to be due. However, please charge any required fee (or credit overpayments) to the Deposit Account of the undersigned, Account No. 500601 (Docket No. 7640-X05-046).

Respectfully submitted,



Paul D. Bianco, Reg. # 43,500
Customer Number: 27317
FLEIT KAIN GIBBONS GUTMAN BONGINI & BIANCO P.L.
21355 East Dixie Highway, Suite 115
Miami, Florida 33180
Tel: 305-830-2600; Fax: 305-830-2605
e-mail: pbianco@focusonip.com

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/559,639	Dina Ben-Yehuda	7640-X05-046

INTERNATIONAL APPLICATION NO.

PCT/IL04/00461

LA. FILING DATE	PRIORITY DATE
-----------------	---------------

05/31/2004

06/02/2003

27317
 FLEIT KAIN GIBBONS GUTMAN BONGINI & BIANCO
 21355 EAST DIXIE HIGHWAY
 SUITE 115
 MIAMI, FL 33180

CONFIRMATION NO. 5095

371 FORMALITIES LETTER



OC000000022644756

Date Mailed: 02/27/2007

COPY**NOTIFICATION OF DEFECTIVE RESPONSE**

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Indication of Small Entity Status
- Priority Document
- Copy of the International Application filed on 12/02/2005
- Copy of the International Search Report filed on 12/02/2005
- Copy of IPE Report filed on 12/02/2005
- Preliminary Amendments filed on 12/02/2005
- Biochemical Sequence Diskette filed on 12/02/2005
- Oath or Declaration filed on 07/24/2006
- Biochemical Sequence Listing filed on 07/24/2006
- Request for Immediate Examination filed on 12/02/2005
- U.S. Basic National Fees filed on 12/02/2005
- Priority Documents filed on 12/02/2005
- Power of Attorney filed on 07/24/2006
- Specification filed on 12/02/2005
- Claims filed on 12/02/2005
- Abstracts filed on 12/02/2005
- Drawings filed on 12/02/2005
- Paper nucleotide sequence listings filed on 12/02/2005

Applicant's response filed 07/24/2006 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 03/24/2006 have not been completed.

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or

compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/559,639	PCT/IL04/00461	7640-X05-046

COPY